慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策*

doi:10.3969/j.issn.1672-5069.2023.06.002

Abstract

Yang RuiXu, Qi Minghua. Antiviral strategy of patients with chronic hepatitis B and concomitant metabolic-dysfunction-related fatty liver diseases[J]. Journal of Practical Hepatology, 2023, 26(6): 773-776.

References

[1] 中华医学会肝病学分会,中华医学会感染病分会. 慢性乙型肝炎防治指南(2022年版). 实用肝脏病杂志,2023,26(3):S18-S39.
[2] 中华医学会肝病学分会.扩大慢性乙型肝炎抗病毒治疗的专家意见.中华肝脏病杂志,2022,30(2):131-136.
[3] 中华医学会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志,2018,37(1):41-45.
[4] Eslam M, Sanyal AJ, George J,et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020,158(7):1999-2014.
[5] Sarin SK,Kumar M,Eslam M,et al. Liver diseases in the Asia-Pacific region:a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol,2020,5(2):167-228.
[6] Zheng Q, Zou B, Wu Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, ﬁbrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther,2021,54:(9):1100-1109.
[7] Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int,2017, 37(4), 542-551.
[8] Wang QX, Xue J, Shi MJ, et al. Association between metabolic dysfunction-associated fatty liver disease and the risk of cirrhosis in patients with chronic hepatitis B-A retrospective cohort study. Diabetes Metab Syndr Obes,2022, 15:2311-2322.
[9] Huang Y, Gan Q, Lai R, et al. Application of fatty liver inhibition of progression algorithm and steatosis, activity, and fibrosis score to assess the impact of non-alcoholic fatty liver on untreated chronic hepatitis B patients. Front Cell Infect Microbiol,2022,11,733348.
[10] Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol,2012,56(3):533-540.
[11] Cheng YL, Wang YJ, Kao WY, et al. Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. PLoS One,2013,8(8):e72049.
[12] Yu MW, Lin CL, Liu CJ, et al. Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors. J Formos Med Assoc,2022, 121(8):1478-1487.
[13] Walter AJ, van de Klundert MA, Jung S. Many ways to communicate-crosstalk between the HBV-infected cell and its environment. Pathogens,2022,12(1):29.
[14] Li J, Yang HI, Yeh ML, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Dis,2021,224(2):294-302.
[15] Shi YW, Yang RX, Fan JG. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. World J Gastroenterol,2021,27(26):3971-3983.
[16] Wang X, Xie Q. Metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis. J Clin Transl Hepatol,2022,10(1):128-133.
[17] Mao X, Cheung KS, Peng C, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis. Hepatology,2023,77(5):1735-1745.
[18] Zhou R, Yang L, Zhang B, et al. Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta-analysis. J Viral Hepat,2023,30(10):793-802.
[19] Di Mauro S, Scamporrino A, Filippello A, et al. Clinical and molecular biomarkers for diagnosis and staging of NAFLD. Int J Mol Sci,2021,22(21):11905.
[20] Kleiner DE, Brunt EM, Wilson LA, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open,2019,2(10):e1912565.

Antiviral strategy of patients with chronic hepatitis B and concomitant metabolic-dysfunction-related fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Song Tao, Xu Min, Dang Zilong, et al. Virologic and biochemical response to entecavir and interferon-α combination therapy in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(6): 785-788.
[2]	Gao Lijuan, Li Yongku, Dong Xinying, et al. Oral tenofovir amibufenamide administration in the treatment of patients with chronic hepatitis B didn’t impact renal functions [J]. Journal of Practical Hepatology, 2023, 26(6): 789-792.
[3]	Zhou Jiying, Xie Yuehong, Yu Cuixia. Decreased biochemical response to entecavir anti-viral therapy in patients with chronic hepatitis B and concomitant non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 793-796.
[4]	Zhang Yue, Ning Ling, Li Wenyuan, et al. 120-week prognosis of serum HBsAg positive patients with chronic renal failure after renal transplantation [J]. Journal of Practical Hepatology, 2023, 26(6): 797-800.
[5]	Zou Tao, Zhang Min, Yang Fan, et al. Implication of peripheral blood mononuclear cell signal transducer and activator of transcription 3 and serum soluble CD30 levels in patients with chronic hepatitis B and hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(6): 855-858.
[6]	He Meinian, Zhao Sijia, Tian Zhichao, et al. Ultrasound semi-quantitative score and elastography in the diagnosis of early liver cirrhosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(6): 871-874.
[7]	Sheng Qiuju, Dou Xiaoguang. Therapeutic strategies and benefit evaluation in patients with chronic hepatitis B viral infection [J]. Journal of Practical Hepatology, 2023, 26(5): 609-611.
[8]	Zhang Dan, Ding Yang. Serum viral loads-oriented disease status and antiviral strategies in patients with chronic hepatitis B viral infection [J]. Journal of Practical Hepatology, 2023, 26(5): 612-614.
[9]	Peng Zhen, Ning Huibin, Li Kuan, et al. Infection staging and antiviral strategy in individuals with chronic serum HBeAg-positive hepatitis B viral infection [J]. Journal of Practical Hepatology, 2023, 26(5): 615-617.
[10]	Huang Baisheng, Ou Lanxin, Zhang Yinjie, et al. Diagnostic performance of FibroScan and GPR, APRI and FIB-4 for liver fibrosis evaluation in patients with chronic hepatitis B virus infection without serum alanine aminotransferase elevation [J]. Journal of Practical Hepatology, 2023, 26(5): 618-621.
[11]	Wu Yulong, Zhuang Jianqi, Liu Zhicheng, et al. Changes of serum HBV pgRNA levels in patients with chronic hepatitis B receiving nucleos(t)ide analogues treatment [J]. Journal of Practical Hepatology, 2023, 26(5): 622-625.
[12]	Wang Yizhuo, Zhang Weiqi, Li Hong. A 3-year follow-up of patients with serum HBeAg-positive chronic hepatitis B after 48 to 72 week pegylated interferon α-2a treatment [J]. Journal of Practical Hepatology, 2023, 26(5): 626-629.
[13]	Hao Anhua, Du Zhongcai, Zhou Lin, et al. Changes of liver stiffness measurement and S index in patients with chronic hepatitis B and their performance in evaluating liver fibrosis [J]. Journal of Practical Hepatology, 2023, 26(5): 630-633.
[14]	Liu Aihua, Fu Jian, Chen Xiaohong. Predicting performance of liver stiffness measurement and GGT/PLT ratio combination in judging liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(5): 634-637.
[15]	Zhou Keli, Lyu Xiaoli, Zhou Yang, et al. Concordance between liver biopsy,and the liver stiffness measurement and hemodynamic index combination for the diagnosis of hepatic fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(4): 480-483.